Send us a text

Inventiva is a clinical-stage biopharmaceutical company that develops novel and differentiated oral small molecule therapies for patients suffering from diseases with significant unmet medical need.

In an exclusive interview, Inventiva's Chief Medical Officer Michael Cooreman joins Stephen Harrison and Roger Green to talk about the company. Specifically, Michael provides detail and color on key elements of the Inventiva clinical development strategy for its pan-PPAR, lanifibranor. The group also discusses the Phase 2b NATIVE trial, Phase 3 NATiV3 trial and combination trial with the SGLT2 inhibitor empagliflozin that had just begun to recruit.

Surf on for a rich conversation and learn more about this innovative company!